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coagulase-negative staphylococcus, 1 (0.9%) Proteus mirabilis, 1
(0.9%) Pseudomonas aeruginosa, 1 (0.9%) Salmonella spp, 1 (0.9%)
Enterobacter aerogenes. The resistance rates of E. coli strains are
given in the table. Among the E. coli strains isolated transplant
recipients, ciprofloxacin resistance rates were 37.5% (3/8) in the
first month after transplantation, 71.4% (15/21) in the period of
the second month to sixth month, and 35.1% (13/37) 6 months af-
ter transplantation. The resistance rates of TMP-SMX in the same
time periods were 100% (8/8), 90.5% (19/21), and 73% (27/37), re-
spectively. See Table 1.
Table 1. The resistance rates of E. coli strains among renal recipients and
the complicated community-acquired UTIs isolates from non-transplant
patients
Antimicrobial agent Renal recipients, Community-acquired, P value
n=66 (%) n=226 (%)
Ampicillin 61 (92.4) 136 (60.2) <0.05
Amoxicillin/clavulanic acid 29 (43.9) 88 (38.9) 0.47
Cefazolin 28 (42.4) 74 (32.7) 0.15
Cefuroxime 21 (31.8) 51 (22.6) 0.12
Ceftriaxone 13 (19.7) 38 (16.8) 0.59
Gentamicin 24 (36.4) 33 (14.6) <0.05
Ciprofloxacin 31 (47.0) 85 (37.6) 0.17
TMP-SMX 54 (81.8) 95 (42.0) <0.05
Conclusion: E. coli was the most frequently isolated organism
from UTIs in renal transplant recipients. The rates of resistance
to TMP-SMX, ampicillin, gentamicin among E. coli isolated from re-
nal recipients were significantly higher than those in community-
acquired complicated UTIs. We have observed that the majority of
the UTIs occurred beyond the sixth month after transplantation,
probably due to the fact that prophylactic TMP-SMX treatment in
renal transplant recipients provides some protection against UTIs.
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Background: The importance role of C. pneumoniae latent infec-
tion in pathogenesis of atherosclerosis is been well known and clin-
ical efficacy of antibiotic therapy has been described. One of the
most important problems in the transplantation field is slow dete-
rioration of transplanted kidney function. Previous research by our
centre pointed to a significant role of C. pneumoniae infection in
the development of chronic renal allograft dysfunction. There are
trials that confirmed C. pneumoniae infection role in liver chronic
rejection and vasculopathy of the transplanted heart. Pathogenesis
of these changes were similar with atherosclerosis.
Objectives: The aim of the study was to evaluate the C. pneu-
moniae presence prior to and after kidney transplantation and to
determine the role of spiramycin therapy in patients after kidney
transplantation.
Material and Methods: The study group consisted of 50 patients
(25 pairs) who received kidney transplants from cadaveric donors.
One of the two kidneys from one donor was transplanted to a pa-
tient randomised to spiramycin (dose of 2x3milion U/day orally for
3 months) (group S) and the other was transplanted to a patient as-
signed as control (group C). Markers of infection were assessed on
day 1 post transplantation and 3 months later (average=94 days).
All (n=50) patients were examined for bacterial DNA presence in
peripheral blood leukocytes using real-time PCR and titers of serum
anti C.pneumoniae IgG and IgA antibodies using microimmunofluo-
rescence (MIF). C. pneumoniae infection was diagnosed as C. pneu-
moniae DNA presence in peripheral blood leukocytes or positive
antibodies titres in both classes IgA (titer>1:16) and IgG (titer
>1:64).
Results: C. pneumoniae infection was initially diagnosed in 14 pa-
tients from group S and in 8 patients from group C (p=ns) after 3
months in 12 and 9 patients respectively (p=ns). Conversion from
positive to negative C. pneumoniae status occurred in 7 patients
from group S and one patient from group C (p=0.04). Conversion
from negative to positive C. pneumoniae status occurred in 5 pa-
tients from group S and 2 patients from group C (p=ns). Negative
C. pneumoniae status during research occurred in 6 patients from
group S and in 15 patients from group C (p= 0.02).
Conclusions: The results suggest a possible role for spiramycin
treatment of in C. pneumoniae infection in kidney allograft re-
cipients. Spiramycin is safe and has no significant interactions with
immunosuppresion treatment in kidney allograft recipients.
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Background: End-stage Chronic Chagas heart disease (ChD) caused
by T. cruzi involves dilated cardiomyopathy, complex arrhythmias,
heart failure and sudden death. Heart transplantation (HT) is a
valid treatment for ChD but reactivation of T. cruzi (RA) is the
main complication of concomitant immunosupression. Natural T.
cruzi populations display different tissue tropisms, growth rates
and drug susceptibility. Their genetic polymorphism supports dis-
tinction of two major lineages: T. cruzi I and II. They have been
identified from cultured stocks, underestimating diversity and pre-
cluding direct association studies of the parasite role with patho-
genesis.
Objectives: To follow-up T. cruzi infection and genotype popula-
tions associated to heart tropism and RA directly in clinical samples
from ChD undergoing HT, using molecular methods.
Methods: 9 ChD patients with a mean follow-up of 907 days
(37–2279 d); routine parasitologic tests and PCR of minicircle DNA
(kDNA) in blood, cardiac explants, endomyocardial biopsies of the
allograft heart and skin lesions. Lineage identification was done
by genomic PCR (Lg-PCR) and intra-lineage typing by RFLP-PCR of
kDNA.
Results: Sections from 7/8 heart explants of ChD were kDNA-PCR+
and 6/7 Lg-PCR+ (2 Tc I, 3 Tc II and 1 both). RFLP-PCR profiles were
polymorphic in different patient' s hearts and also among sections
of a same explant. Between 1-3 and 1-6 weeks after HT, kDNA-PCR
and Lg-PCR turned into positive in the 9 patients, showing recrude-
scence of infection leading in 6 to patent parasitemia concomitant
with RA within a mean period of 71.6 days. 4/9 ChD had TcI and
5/9 Tc II in blood. Lg-PCR was positive earlier in Tc II than in Tc I
infections. 5/6 RA patients developed lower limbs skin lesions and
1 chagasic myocarditis; in 5 patients identical lineages and RFLP-
